Загрузка...
Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available therapies for CML,...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4180713/ https://ncbi.nlm.nih.gov/pubmed/21509757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25717 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|